NCT04436029: Phase 2: Descartes-11 Consolidation Treatment Patients With High-Risk Multiple Myeloma

NCT04436029: Phase 2: Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following induction therapy.

Sponsor

Cartesian Therapeutics

Multiple Locations

---

ClinicalTrials.gov Identifier: NCT04436029

Official Title: Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

First Posted : June 17, 2020

Click here to see details on ClinicalTrials.gov

---

Biological: Descartes 11 Car T-cells

---

Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11

Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11 (Code C173434)

Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11

Autologous CD8+ T-cells Expressing Anti-BCMA CAR Descartes-11

Descartes 11

Descartes-011

Descartes-11

Descartes11

---

Locations

United States, Maryland

United States, New Jersey

United States, Oklahoma

United States, Wisconsin